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Purpose: TNF-α has been suggested to participate in the pathogenesis of exfoliation glaucoma (XFG). The purpose of
the present study was to investigate a hypothesized association between two common functional polymorphisms in the
promoter region of the TNF-α gene (TNF-α –308 G>A, rs1800629, and TNF-α –238 G>A, rs361525) and the presence
of XFG in a Caucasian population.
Methods: The present case-control study comprised 408 participants (204 patients with XFG and 204 control subjects).
Control subjects were matched for age and sex. Genotypes of the TNF-α –308 G>A and TNF-α –238 G>A polymorphisms
were determined by polymerase chain reaction (restriction fragment length polymorphism).
Results: No significant differences regarding genotype distribution or allelic frequencies were found between patients
and control subjects (p>0.025). The presence of the TNF-α –308 G-allele was associated with an insignificant odds ratio
of 0.98 (95% confidence interval [CI]: 0.66–1.46; p=0.99) while the presence of the TNF-α –238 G-allele was associated
with an insignificant odds ratio of 0.64 (95% CI: 0.33–1.23; p=0.25).
Conclusions: Our data suggest that both the TNF-α –308 G>A and the TNF-α –238 G>A polymorphisms are unlikely to
be major risk factors for XFG in an European population of Caucasian descent.
Exfoliation  syndrome  (XFS;  OMIM  177650)  is
recognized  as  a  general  elastic  fibrillopathy,  leading  to
accumulation of characteristic abnormal fibrillar material in
different  intra-  and  extraocular  tissues,  e.g.,  trabecular
meshwork, iris stroma, conjunctiva, kidney, lung, and heart
[1,2]. Glaucomatous optic neuropathy due to XFS (exfoliation
glaucoma,  XFG)  is  caused  by  deposition  of  exfoliation
material and liberated iris pigment in the trabecular meshwork
leading to elevation of intraocular pressure [3]. Results from
family-based studies and from a study investigating the loss
of heterozygosity in specimens of the anterior segment in
individuals with XFS indicate a high grade of heritability of
XFS [4-8]. Recently, two common non-synonymous single
nucleotide  polymorphisms  (SNPs;  rs1048661  and
rs3825942) in the lysyl oxidase-like protein 1 gene (LOXL1;
OMIM 153456) that confer increased risk for the development
of XFS and XFG have been identified [9]. However, as the
prevalences  of  these  polymorphisms  are  also  high  in
individuals without XFS, other, as yet unkown genetic or
enviromental factors may be involved [10-16].
The  degradation  of  the  extracellular  matrix  (ECM)
depends  on  the  activity  of  a  group  of  highly  regulated
endopeptidases named matrix metalloproteinases (MMPs),
which are grouped in four families consisting of 23 members
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in  total,  each  with  a  specific  spectrum  of  ligands  [17].
Uncontrolled  activation  of  MMPs  is  counterbalanced  by
specific tissue inhibitors of metalloproteinases (TIMPs), and
a  delicate  balance  of  MMPs  and  TIMPs  is  required  for
physiologic ECM turnover. Interestingly, increased levels of
TIMP-1 and TIMP-2 and decreased levels of MMP-2 have
been detected in the aqueous humor of patient with XFS [18,
19]. An impaired balance between MMPs and TIMPs may
thus contribute to the development of XFS.
Tumor necrosis factor-alpha (TNF-α, OMIM 191160) is
a ubiquitous cytokine involved in various physiologic as well
as  pathologic  processes  like  inflammation,
immunoregulation, proliferation, and apoptosis [20]. Notably,
several in vitro studies provided evidence that TNF-α is also
capable of inducing both increased synthesis and activity of
MMPs [21-24].
Two common functional polymorphisms in the promoter
region  of  TNF-α  have  been  identified.  The  first  is
characterized by a G to A substitution at position –308 (TNF-
α –308 G>A, rs1800629) while the second is characterized by
a G to A substitution at position −238 (TNF-α –238 G>A,
rs361525). In vitro studies of these polymorphisms have been
shown to increase TNF-α production after lipopolysaccharide
stimulation [25-27]. Other studies, however, were unable to
confirm this effect on TNF-α synthesis [27-29].
Only  recently,  Tekeli  and  coworkers  [30]  found  an
increased prevalence of the TNF-α −308 GG genotype among
110 Turkish patients with XFG. This finding, however, has
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518not  yet  been  confirmed  in  other  populations,  which  is
mandatory to draw firm conclusions on the role of TNF-α
polymorphisms.  Our  study  was  set  to  investigate  a
hypothesized association between the TNF-α –308 G>A and
TNF-α –238 G>A polymorphisms and the presence of XFG.
METHODS
Two hundred and four unrelated patients with XFG and 204
control subjects were enrolled in the present retrospective
case-control study. All study participants were Caucasians
from  the  same  geographical  area  in  the  southern  part  of
Austria.  Participants  were  seen  at  the  Department  of
Ophthalmology,  Medical  University  Graz  (Graz,  Austria)
between May 2003 and September 2008 and gave informed
written consent before enrollment. The study was conducted
in accordance with the National Gene Technology Act of
Austria and the guidelines of the local ethics committee.
Patients with XFG underwent slit lamp biomicroscopy in
mydriasis, testing for best corrected visual acuity, Goldmann
applanation  tonometry,  gonioscopy,  pachymetry,  and
standard automated perimetry (Octopus 101, program G2;
Interzeag, Schlieren, Switzerland) or in cases of profoundly
decreased  visual  acuity,  Goldmann  perimetry.  Control
subjects  underwent  slit  lamp  biomicroscopy  in  mydriasis,
Goldmann  applanation  tonometry,  and  testing  for  best
corrected visual acuity. Optic discs in all participants were
assessed by glaucoma specialists (C.F., G.M.).
XFG was defined by the presence of typical exfoliation
material on the anterior lens capsule, an intraocular pressure
before initiation of a pressure lowering therapy of at least
22 mmHg, an open anterior chamber angle, optic disc changes
characteristic  for  glaucoma  (notching,  thinning  of  the
neuroretinal rim, increased cup/disc ratio in relation to the
optic  disc  size),  visual  field  defects  characteristic  for
glaucoma (inferior or superior arcuate scotoma, nasal step,
paracentral scotoma), and absence of conditions leading to
secondary glaucoma.
Control subjects showed biomicroscopically no evidence
of exfoliation material on the anterior capsule of the lens and
no morphological damage indicative for open-angle or angle
closure  glaucoma.  Control  subjects  were  admitted  to  our
department for cataract surgery.
Genotype determination: Venous blood was collected in
5 ml EDTA tubes. DNA was isolated using QIAamp DNA
blood mini-kit (QIAGEN, Venlo, Netherlands) and stored at
−20 °C. All polymerase chain reactions (PCRs) were run
under conditions previously described [31]. Primer sequences
for the gene polymorphism at –308 were forward 5′-GGG
ACA CAC AAG CAT CAA GG-3′ and reverse 5′-GGG ACA
CAC AAG CAT CAA GG-3′, for the polymorphism at −238
forward  5′-ATC  TGG  AGG  AAG  CGG  TAG  TG-3′  and
reverse 5′-AGA AGA CCC CCC TCG GAA CC-3′. DNA
samples were amplified in 25 µl aliquots containing 200 µM
deoxynucleoside triphosphate, 10 µM of each primer, 1.5 mM
MgCl2, 1 µl DNA sample, and 2 U Taq polymerase (Applied
Biosystems, Foster City, CA). Annealing temperature was
62 °C. The PCR products were digested at 37 °C with NcoI
to detect the SNP in the −308 gene allele and MspI to detect
the polymorphism of the −238 nucleotide. The PCR product
was then subjected to 3% agarose-gel electrophoresis. “No
target” controls were included in each PCR batch to ensure
that reagents had not been contaminated.
Statistical analysis: Descriptive statistics were used to
calculate frequencies and percentages of discrete variables.
Continuous data are given as mean±standard deviation (SD).
Means  were  compared  using  the  Mann–Whitney  test.
Proportions of groups were compared by the χ2 test. The odds
ratio  (OR)  and  95%  confidence  interval  (95%  CI)  were
calculated by logistic regression. According to the Bonferroni
correction, the criterion for statistical significance was set at
p≤0.025. Hardy–Weinberg equilibrium has been calculated
using HW Diagnostics-Version 1.beta (Fox Chase Cancer
Center, Philadelphia, PA). Statistical analysis was done using
the SPSS statistical package (version 14.0; SPSS, Chicago,
IL).
RESULTS
The present study comprised of 204 patients with XFG (118
female and 86 male) and 204 control subjects, all matched for
age and gender. The mean age of patients with XFG was
76.1±7.0 years (range: 60.6–91.7 years), and the mean age for
control subjects was 75.3±6.9 years (range: 60.3–93.1 years).
The observed genotype distributions did not deviate from
those predicted by the Hardy–Weinberg equilibrium, and for
control  subjects,  they  were  similar  to  those  reported  for
Caucasian populations [32]. Table 1 shows the genotype and
allele frequencies of TNF-α –308 G>A and TNF-α −238 G>A
polymorphisms in patients with XFG and control subjects. No
significant  differences  in  either  genotype  distribution  or
allelic frequencies of the TNF-α –308 G>A and the TNF-α
−238 G>A polymorphisms were found between patients with
XFG and control subjects. The presence of the TNF-α –308
G-allele was associated with an insignificant odds ratio of 0.98
(95% CI: 0.66–1.46; p=0.99) for XFG. An insignificant odds
ratio of 0.64 (95% CI: 0.33–1.23; p=0.25) for XFG was also
found among carriers of the TNF-α –238 G-allele. The present
study had a statistical power of 0.80 to detect an odds ratio
≥2.09 for the TNF-α –308 G/G genotype and an odds ratio
≥4.19 for the TNF-α −238 G/G genotype in patients with XFG.
DISCUSSION
TNF-α has been shown to affect activity and synthesis of
MMPs and TIMPs, which play a major role in the turnover of
the ECM in the trabecular meshwork. Treatment of rat cardiac
fibroblasts  with  TNF-α  exhibited  an  increased  activity  of
MMP-2, MMP-9, and MMP-13, while stimulation of human
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MMP-3, and MMP-9 [21,24]. Furthermore, in an in vitro
study  using  human  endothelial  cells,  TNF-α  induced
increased levels of MMP-14, which in turn activated latent
MMP-2 [22]. In mouse osteoblastic cells, mRNA levels of
MMP-3,MMP-9,TIMP-1, and TIMP-3 were upregulated by
TNF-α [23].
Various  studies  provided  evidence  that  MMPs  and
TIMPs  may  be  involved  in  the  pathogenesis  of  XFG.
Schlötzer-Schrehardt and coworkers found a decreased ratio
of MMP-2 to TIMP-2 in the aqueous humor of patients with
XFG, which has been corroborated by Määttä and coworkers
[18,19].  Ho  and  coworkers  [33]  reported  significantly
increased levels of TIMP-1 in the aqueous humor of patients
with XFS, while in an immunohistochemical study Rönkkö
and coworkers [34] found decreased ratios of MMPs to TIMPs
in  trabecular  meshwork  specimens  of  patients  with  XFG.
Remarkably,  Tekeli  and  coworkers  [30]  investigating  the
common  functional  TNF-α  –308  G>A  polymorphism
suggested  that  this  polymorphism  may  exert  protection
against XFG. In their study that included 110 patients with
XFG, 6.4% of the patients with XFG were found to have the
heterozygote TNF-α –308 GA genotype compared to 16.4%
of the control subjects. In the present study, no significant
differences were found in the genotype distribution or allelic
frequency of the TNF-α –308 G>A polymorphism as was the
case  for  the  TNF-α  −238  G>A  polymorphism.  An
insignificant odds ratio for XFG was found in both carriers of
the TNF-α −308 G-allele and of the TNF-α −238 G-allele,
suggesting  that  these  polymorphisms  themselves  are  not
major risk factors for XFG. Possible explanations for these
conflicting results may include small sample size as well as
varying genotype distributions among different populations.
A  limitation  of  the  present  study  is  the  sample  size,
whereby  minor  genetic  effects  may  be  undetected.
Furthermore, it can not be ruled out that other, as yet unknown
functional  polymorphisms  in  the  TNF-α  gene  influence
susceptibility to XFG.
The  TNF-α  –308  G>A  polymorphism  has  also  been
recently implicated in the pathogenesis of primary open-angle
glaucoma. An increased prevalence of the TNF-α −308 A-
allele  was  reported  in  patients  with  primary  open-angle
glaucoma in a Chinese study, albeit this result could not be
replicated in subsequent studies [35-37].
In conclusion, based on the results of the present study,
neither  the  TNF-α  –308  G>A  nor  the  TNF-α  −238  G>A
polymorphism is a major risk factor among Caucasian patients
with XFG.
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